Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Earnings for Omeros Corporation (OMER)
Earnings in 2023 (TTM): $-174,920,000
According to Omeros Corporation's latest financial reports the company's current earnings (TTM) are $-174,920,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Omeros Corporation
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-174,920,000 | $-117,813,000 |
| 2022 | $-182,029,000 | $28.78 M |
| 2021 | $-191,546,000 | $194.24 M |
| 2020 | $-150,072,000 | $-138,061,000 |
| 2019 | $-84,486,000 | $-106,906,000 |
| 2018 | $-139,686,000 | $-126,757,000 |
| 2017 | $-53,481,000 | $-53,481,000 |
| 2016 | $-66,745,000 | $-66,745,000 |
| 2015 | $-75,096,000 | $-75,096,000 |
| 2014 | $-73,673,000 | $-73,673,000 |
| 2013 | $-39,796,000 | $-39,796,000 |
| 2012 | $-38,444,000 | $-38,444,000 |
| 2011 | $-26,662,000 | $-28,546,000 |
| 2010 | $-27,716,000 | $-29,251,000 |
| 2009 | $-18,887,000 | $-21,089,000 |
| 2008 | $-23,827,000 | $-23,827,000 |
| 2007 | $-23,091,000 | $-23,091,000 |
| 2006 | $-22,777,000 | $-22,777,000 |